Moderna announced Monday that a third dose of its mRNA vaccine against Covid-19 appears to provide significant protection against the omicron variant.
However, it said it will also continue to develop an omicron-specific booster candidate which should enter clinical trials in early 2022.
Modern said that its currently authorized booster can “boost neutralizing antibody levels 37-fold higher than pre-boost levels,” which it described as reassuring.
https://www.cnbc.com/2021/12/20/mod...nt=Main&utm_source=Twitter#Echobox=1639998159
However, it said it will also continue to develop an omicron-specific booster candidate which should enter clinical trials in early 2022.
Modern said that its currently authorized booster can “boost neutralizing antibody levels 37-fold higher than pre-boost levels,” which it described as reassuring.
https://www.cnbc.com/2021/12/20/mod...nt=Main&utm_source=Twitter#Echobox=1639998159